A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials.

BMC Pulm Med · 2024 · PMC10822186 · PMID 38281037

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a phase 1 RCT of increasing doses of PRM-151, the results showed a trend towards improvement in FVC and 6-MWT in the combined dose group of PRM-151 and no SAEs [ 43 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.